Aviv Philip Goncharov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aviv Philip Goncharov has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Bohuslav Melichar
Department of Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, Olomouc, Czech Republic
1 shared publicationConstantinos Dicusari Elissaiou
Department of Clinical and Molecular Pathology, Palacky University
1 shared publicationDaniela Skanderova
Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, Olomouc, Czech Republic
1 shared publicationElad Ben Aharon Farzalla
Department of Clinical and Molecular Pathology, Palacky University
1 shared publicationGiorgi Akhvlediani
Faculty of Medicine, Georgian-American University
1 shared publicationGvantsa Kharaishvili
Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, Olomouc, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Discover Oncology
A case report of perioperative immune checkpoint inhibitor therapy achieving long-term disease control in TFEB-amplified renal cell carcinoma
- 28 September 2026
- Published by Springer Nature in Discover Oncology
Open AccessA case report of perioperative immune checkpoint inhibitor therapy achieving long-term disease control in TFEB-amplified renal cell carcinoma
- Open Access
- 15 May 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2474175
Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer
From tumorigenesis to the establishment of local or metastatic high-grade tumours, an integral part of the cellular lifespan relies on various signalling pathways. Particular pathways that allow cells to proliferate by creating a network of new blood vessels have been documented, whereas other pathways are primarily involved with a migration to distant body parts, partially through the process of epithelial-mesenchymal transition (EMT). This review will discuss the different signalling pathways, such as TGF-β, Cripto-1, Wnt pathways, Hedgehog, Notch and NF-κB pathways, and how they promote tumour initiation and progression by influencing diverse cellular processes and EMT in general and in benign and malignant prostate tumours. This review will discuss only the critical pathways. Therefore, many other types of signalling pathways which are related to prostate cancer will not be discussed. Possibilities for further investigation will be mentioned, as many underlying mechanisms involved in these pathways have potential as targets in future tumour therapy. This review will also introduce some novel clinical trials relating to the inhibition of signalling pathways and their clinical outcomes.
- 15 May 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2474175
Open AccessSignalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer
From tumorigenesis to the establishment of local or metastatic high-grade tumours, an integral part of the cellular lifespan relies on various signalling pathways. Particular pathways that allow cells to proliferate by creating a network of new blood vessels have been documented, whereas other pathways are primarily involved with a migration to distant body parts, partially through the process of epithelial-mesenchymal transition (EMT). This review will discuss the different signalling pathways, such as TGF-β, Cripto-1, Wnt pathways, Hedgehog, Notch and NF-κB pathways, and how they promote tumour initiation and progression by influencing diverse cellular processes and EMT in general and in benign and malignant prostate tumours. This review will discuss only the critical pathways. Therefore, many other types of signalling pathways which are related to prostate cancer will not be discussed. Possibilities for further investigation will be mentioned, as many underlying mechanisms involved in these pathways have potential as targets in future tumour therapy. This review will also introduce some novel clinical trials relating to the inhibition of signalling pathways and their clinical outcomes.
- Open Access
- 11 February 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (2) , 418
Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies
Epithelial-mesenchymal transition (EMT) is a crucial and fundamental mechanism in many cellular processes, beginning with embryogenesis via tissue remodulation and wound healing, and plays a vital role in tumorigenesis and metastasis formation. EMT is a complex process that involves many transcription factors and genes that enable the tumor cell to leave the primary location, invade the basement membrane, and send metastasis to other tissues. Moreover, it may help the tumor avoid the immune system and establish radioresistance and chemoresistance. It may also change the normal microenvironment, thus promoting other key factors for tumor survival, such as hypoxia-induced factor-1 (HIF-1) and promoting neoangiogenesis. In this review, we will focus mainly on the role of EMT in benign prostate disease and especially in the process of establishment of malignant prostate tumors, their invasiveness, and aggressive behavior. We will discuss relevant study methods for EMT evaluation and possible clinical implications. We will also introduce clinical trials conducted according to CONSORT 2010 that try to harness EMT properties in the form of circulating tumor cells to predict aggressive patterns of prostate cancer. This review will provide the most up-to-date information to establish a keen understanding of the cellular and microenvironmental processes for developing novel treatment lines by modifying or blocking the pathways.
- 11 February 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (2) , 418
Open AccessEpithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies
Epithelial-mesenchymal transition (EMT) is a crucial and fundamental mechanism in many cellular processes, beginning with embryogenesis via tissue remodulation and wound healing, and plays a vital role in tumorigenesis and metastasis formation. EMT is a complex process that involves many transcription factors and genes that enable the tumor cell to leave the primary location, invade the basement membrane, and send metastasis to other tissues. Moreover, it may help the tumor avoid the immune system and establish radioresistance and chemoresistance. It may also change the normal microenvironment, thus promoting other key factors for tumor survival, such as hypoxia-induced factor-1 (HIF-1) and promoting neoangiogenesis. In this review, we will focus mainly on the role of EMT in benign prostate disease and especially in the process of establishment of malignant prostate tumors, their invasiveness, and aggressive behavior. We will discuss relevant study methods for EMT evaluation and possible clinical implications. We will also introduce clinical trials conducted according to CONSORT 2010 that try to harness EMT properties in the form of circulating tumor cells to predict aggressive patterns of prostate cancer. This review will provide the most up-to-date information to establish a keen understanding of the cellular and microenvironmental processes for developing novel treatment lines by modifying or blocking the pathways.